Cohort profile: the Finnish Medication and Alzheimer's disease (MEDALZ) study

BMJ Open

Volumn 6, Issue 7, 2016, Pages

  Tolppanen, Anna Maija ^a   Taipale, Heidi ^a,c   Koponen, Marjaana ^a   Lavikainen, Piia ^a   Tanskanen, Antti ^a,b,c   Tiihonen, Jari ^a,c   Hartikainen, Sirpa ^a,d  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c KAROLINSKA INSTITUTE   (Sweden)

^d KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; PSYCHOTROPIC AGENT;

ADULT; AGED; ALZHEIMER DISEASE; COHORT ANALYSIS; COMPLICATION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG MONITORING; DRUG SCREENING; FEMALE; FINLAND; HUMAN; MALE; MIDDLE AGED; PATIENT ATTITUDE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIDEPRESSIVE AGENTS; BENZODIAZEPINES; COHORT STUDIES; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EVALUATION; DRUG MONITORING; FEMALE; FINLAND; HUMANS; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PSYCHOTROPIC DRUGS;

EID: 85006478603     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/BMJOPEN-2016-012100     Document Type: Article

References (37)

1. Murray CJ, Barber RM, Foreman, KJ, et al. GBD 2013 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet 2015;386:2145-91.
2. Alzheimer's Association. 2016 Alzheimer's disease facts and figures. Alzheimers Dement 2016;12:459-509.
3. World Health Organization. Dementia: a public health priority. Geneva: WHO. 2012.
4. Leinonen A, Koponen M, Hartikainen S. Systematic review: representativeness of participants in RCTs of acetylcholinesterase inhibitors. PLoS ONE 2015;10:e0124500.
5. Taipale H, Koponen M, Tanskanen A, et al. High prevalence of psychotropic drug use among persons with and without Alzheimer's disease in Finnish nationwide cohort. Eur Neuropsychopharmacol 2014;24:1729-37.
6. Taipale H, Tanskanen A, Koponen M, et al. Antidementia drug use among community-dwelling individuals with Alzheimer's disease in Finland: a nationwide register-based study. Int Clin Psychopharmacol 2014;29:216-23.
7. Koponen M, Taipale H, Tanskanen A, et al. Long-term use of antipsychotics among community-dwelling persons with Alzheimer's disease: a nationwide register-based study. Eur Neuropsychopharmacol 2015;25:1706-13.
8. Cusack BJ. Pharmacokinetics in older persons. Am J Geriatr Pharmacother 2004;2:274-302.
9. Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 2004;57:6-14.
10. Working group appointed by the Finnish Medical Society Duodecim, Societas Gerontologica Fennica, the Finnish Neurological Society, Finnish Psychogeriatric Association and the Finnish Association for General Practice. Finnish current care recommendation: Memory disorders. 2010.
11. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
12. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Washington DC: American Psychiatric Association, 1994.
13. Furu K, Wettermark B, Andersen M, et al. The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol 2010;106:86-94.
14. Tolppanen AM, Taipale H, Koponen M, et al. Use of existing data sources in clinical epidemiology: Finnish healthcare registers in Alzheimer's disease research-the Medication use among persons with Alzheimer's disease (MEDALZ-2005) study. Clin Epidemiol 2013;5:277-85.
15. Taipale H, Purhonen M, Tolppanen AM, et al. Hospital care and drug costs from five years before until two years after the diagnosis of Alzheimer's disease in a Finnish nationwide cohort. Scand J Public Health 2016;44:150-8.
16. Tolppanen AM, Taipale H, Purmonen T, et al. Hospital admissions, outpatient visits and healthcare costs of community-dwellers with Alzheimer's disease. Alzheimers Dement 2015;11:955-63.
17. Tanskanen A, Taipale H, Koponen M, et al. From prescription drug purchases to drug use periods-a second generation method (PRE2DUP). BMC Med Inform Decis Mak 2015;15:21.
18. Guidelines for ATC classification and DDD assignment 2012. (accessed 15 Mar 2012).
19. Puranen A, Taipale H, Koponen M, et al. Incidence of antidepressant use in community-dwelling persons with and without Alzheimer's disease-13-year follow-up. Int J Geriatr Psychiatry 2016.
20. Saarelainen L, Taipale H, Koponen M, et al. The incidence of benzodiazepine and related drug use in persons with and without Alzheimer's disease. J Alzheimers Dis 2015;49:809-18.
21. Gissler M, Shelley J. Quality of data on subsequent events in a routine Medical Birth Register. Med Inform Internet Med 2002;27:33-8.
22. Isohanni M, Makikyro T, Moring J, et al. A comparison of clinical and research DSM-III-R diagnoses of schizophrenia in a Finnish national birth cohort. Clinical and research diagnoses of schizophrenia. Soc Psychiatry Psychiatr Epidemiol 1997;32:303-8.
23. Teppo L, Pukkala E, Lehtonen M. Data quality and quality control of a population-based cancer registry. Experience in Finland. Acta Oncol 1994;33:365-9.
24. Tolonen H, Salomaa V, Torppa J, et al. The validation of the Finnish Hospital Discharge Register and Causes of Death Register data on stroke diagnoses. Eur J Cardiovasc Prev Rehabil 2007;14:380-5.
25. Meretoja A, Kaste M, Roine RO, et al. Trends in treatment and outcome of stroke patients in Finland from 1999 to 2007. PERFECT Stroke, a nationwide register study. Ann Med 2011;43(Suppl 1): S22-30.
26. Sund R, Nurmi-Lüthje I, Lüthje P, et al. Comparing properties of audit data and routinely collected register data in case of performance assessment of hip fracture treatment in Finland. Methods Inf Med 2007;46:558-66.
27. Mähönen M, Salomaa V, Torppa J, et al. The validity of the routine mortality statistics on coronary heart disease in Finland: comparison with the FINMONICA MI register data for the years 1983-1992. Finnish multinational MONItoring of trends and determinants in CArdiovascular disease. J Clin Epidemiol 1999;52:157-66.
28. Pajunen P, Koukkunen H, Ketonen M, et al. The validity of the Finnish Hospital Discharge Register and Causes of Death Register data on coronary heart disease. Eur J Cardiovasc Prev Rehabil 2005;12:132-7.
29. Rapola JM, Virtamo J, Korhonen P, et al. Validity of diagnoses of major coronary events in national registers of hospital diagnoses and deaths in Finland. Eur J Epidemiol 1997;13:133-8.
30. Solomon A, Ngandu T, Soininen H, et al. Validity of dementia and Alzheimer disease diagnoses in Finnish national registers. Alzheimers Dement 2014;10:303-9.
31. Tolppanen AM, Lavikainen P, Solomon A, et al. History of medically treated diabetes and risk of Alzheimer disease in a nationwide case-control study. Diabetes Care 2013;36:2015-9.
32. Tolppanen AM, Lavikainen P, Soininen H, et al. Incident hip fractures among community dwelling persons with Alzheimer's disease in a Finnish nationwide register-based cohort. PLoS ONE 2013;8:e59124.
33. Profenno LA, Porsteinsson AP, Faraone SV. Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders. Biol Psychiatry 2010;67:505-12.
34. Weller I, Schatzker J. Hip fractures and Alzheimer's disease in elderly institutionalized Canadians. Ann Epidemiol 2004;14: 319-24.
35. Zhao Y, Kuo TC, Weir S, et al. Healthcare costs and utilization for Medicare beneficiaries with Alzheimer's. BMC Health Serv Res 2008;8:108.
36. Baker NL, Cook MN, Arrighi HM, et al. Hip fracture risk and subsequent mortality among Alzheimer's disease patients in the United Kingdom, 1988-2007. Age Ageing 2011;40:49-54.
37. Trimpou P, Landin-Wilhelmsen K, Odén A, et al. Male risk factors for hip fracture-a 30-year follow-up study in 7, 495 men. Osteoporos Int 2010;21:409-16.